1
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Sahai E: Illuminating the metastatic
process. Nat Rev Cancer. 7:737–749. 2007. View Article : Google Scholar : PubMed/NCBI
|
3
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
4
|
Lu J, Guo H, Treekitkarnmongkol W, et al:
14-3-3ζ cooperates with ErbB2 to promote progression of ductal
carcinoma in situ progression to invasive breast cancer by inducing
epithelial-mesenchymal transition. Cancer Cell. 16:195–207.
2009.
|
5
|
Mani SA, Guo W, Liao MJ, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
6
|
Buchwald M, Krämer OH and Heinzel T: HDACi
- targets beyond chromatin. Cancer Lett. 280:160–167. 2009.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Acharya MR, Sparreboom A, Venitz J and
Figg WD: Rational development of histone deacetylase inhibitors as
anticancer agents: a review. Mol Pharmacol. 68:917–932. 2005.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Yoshikawa M, Hishikawa K, Marumo T and
Fujita T: Inhibition of histone deacetylase activity suppresses
epithelial-to-mesenchymal transition induced by TGF-beta1 in human
renal epithelial cells. J Am Soc Nephrol. 18:58–65. 2007.
View Article : Google Scholar
|
9
|
Bruzzese F, Leone A, Rocco M, et al: HDAC
inhibitor vorinostat enhances the antitumor effect of gefitinib in
squamous cell carcinoma of head and neck by modulating ErbB
receptor expression and reverting EMT. J Cell Physiol.
226:2378–2390. 2011. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kong D, Ahmad A, Bao B, et al: Histone
deacetylase inhibitors induce epithelial-to-mesenchymal transition
in prostate cancer cells. PloS One. 7:e450452012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View
Article : Google Scholar : PubMed/NCBI
|
12
|
Scheel C, Eaton EN, Li SH, et al:
Paracrine and autocrine signals induce and maintain mesenchymal and
stem cell states in the breast. Cell. 145:926–940. 2011. View Article : Google Scholar : PubMed/NCBI
|
13
|
Roth SY, Denu JM and Allis CD: Histone
acetyltransferases. Annu Rev Biochem. 70:81–120. 2001. View Article : Google Scholar : PubMed/NCBI
|
14
|
Dokmanovic M, Clarke C and Marks PA:
Histone deacetylase inhibitors: overview and perspectives. Mol
Cancer Res. 5:981–989. 2007. View Article : Google Scholar : PubMed/NCBI
|
15
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
16
|
Juan LJ, Shia WJ, Chen MH, et al: Histone
deacetylases specifically down-regulate p53-dependent gene
activation. J Biol Chem. 275:20436–20443. 2000. View Article : Google Scholar
|
17
|
Ashburner BP, Westerheide SD and Baldwin
AS Jr: The p65 (RelA) subunit of NF-kappaB interacts with the
histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to
negatively regulate gene expression. Mol Cell Biol. 21:7065–7077.
2001. View Article : Google Scholar : PubMed/NCBI
|
18
|
Winer IS, Bommer GT, Gonik N and Fearon
ER: Lysine residues Lys-19 and Lys-49 of beta-catenin regulate its
levels and function in T cell factor transcriptional activation and
neoplastic transformation. J Biol Chem. 281:26181–26187. 2006.
View Article : Google Scholar
|
19
|
Li VS, Ng SS, Boersema PJ, et al: Wnt
signaling through inhibition of beta-catenin degradation in an
intact Axin1 complex. Cell. 149:1245–1256. 2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Li Y, Zhang X, Polakiewicz RD, et al:
HDAC6 is required for epidermal growth factor-induced beta-catenin
nuclear localization. J Biol Chem. 283:12686–12690. 2008.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Mak AB, Nixon AM, Kittanakom S, et al:
Regulation of CD133 by HDAC6 promotes β-catenin signaling to
suppress cancer cell differentiation. Cell Rep. 2:951–963.
2012.PubMed/NCBI
|
22
|
Bi X, Pohl N, Qian Z, et al:
Decorin-mediated inhibition of colorectal cancer growth and
migration is associated with E-cadherin in vitro and in mice.
Carcinogenesis. 33:326–330. 2012. View Article : Google Scholar : PubMed/NCBI
|